Checkpoints and immunity in cancers: Role of GNG12

Cancer progression is enhanced through cell proliferation, with the crucial role of the transducer and transmembrane –signal regulator (GNG12) bringing it to the fore. Dysregulation of cancer cell metabolism, evasion of the immune system, cell cycle, apoptosis, and chemoresistance result from incons...

Full description

Saved in:

Bibliographic Details
Published in:	Pharmacological research Vol. 180; p. 106242
Main Authors:	Alausa, Abdullahi, Victor, Ugwu Chukwuebuka, Fadahunsi, Olumide Samuel, Owolabi, Nurudeen, Adeniji, Adeolu, Olatinwo, Mercy, Ogunlana, Abdeen Tunde, Olaleke, Barakat, Balogun, Toheeb Adewale, Ogundepo, Sunday, Adegbola, Peter Ifeoluwa
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 01-06-2022 Elsevier
Subjects:	Cancer GNG12 Immune Checkpoint Inhibitors Immune System NF-kB IDO 1 TCR WES NF-kB MHC SiRNA EGFR Immune System LAG-3 PD-L1 CTLA4 Shp PSC CDKN2A Immune Checkpoint Inhibitors SIRPα IPMN MAPK GNG12 PDAC PI3k PDGF PanIN CD28 MCN KRAS CD47 PD-1 Cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Cancer progression is enhanced through cell proliferation, with the crucial role of the transducer and transmembrane –signal regulator (GNG12) bringing it to the fore. Dysregulation of cancer cell metabolism, evasion of the immune system, cell cycle, apoptosis, and chemoresistance result from inconsistent initiation of the NF-kB signaling pathway. We excerpt from previous studies that overactivation of the canonic NF-kB cascade occurs in varieties of tumor cells, which results in the growth of lymphovascular invasion, as well as neural invasion. Recently, research has adduced that a particular G protein- coupled receptor (GNG12) is silently involved in the activation of the NF-kB signal, which supports the evasion of cancer immunity and in turn activates cancer proliferation, angiogenesis, and immunotherapeutic resistance. While the likely impact of GNG12 in relation to the progression of tumors is being established, there is insufficient knowledge regarding the functions and mechanisms of GNG12 in cancer immunity. Furthermore, the cancer-associated role as well as the clinical correlation of GNG12 have long been unknown; thus, their identification is more likely to pave the path for a novel regime of tumor suppression. In this study, we established the silent role of GNG12 in activating NF-kB genes and the synergism between NF-kB and PD-L1 expression. Captivatingly, we reported that silencing GNG12 gene downregulates the transcription of PD-L1 gene. We therefore suggested that GNG12 is a risk factor for several cancers, and a possible target for immunotherapy. [Display omitted]
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1
ISSN:	1043-6618 1096-1186
DOI:	10.1016/j.phrs.2022.106242